Literature DB >> 9862789

Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.

S Döppenschmitt1, P Langguth, C G Regårdh, T B Andersson, C Hilgendorf, H Spahn-Langguth.   

Abstract

Interaction with the exsorptive transporter P-glycoprotein (P-gp) is a possible source of peculiarities in drug pharmacokinetics, including dose-dependent absorption, drug-drug interactions, intestinal secretion, and limited permeability of the blood-brain barrier. Among the established in vitro methods of the analysis of drug interactions with P-gp, none directly quantifies the affinity of ligands with P-gp. Instead, they measure the result of a membrane permeation and a receptor-binding process; this may lead to difficulties in the interpretation of results. An assay for quantification of drug affinity to the transporter is presented on the basis of the radioligand-binding assay principle. This has the advantage of directly quantifying the interaction between drugs and P-gp. Because of the reversible and competitive interaction of numerous substrates with P-gp, a radioligand-binding assay was developed by taking [3H]verapamil and [3H]vinblastine as radioligands and the human intestinal Caco-2 cells, overexpressed with P-gp by culturing in the presence of vinblastine or transfecting with multidrug resistance gene MDR-1 as receptor preparation. The assay was performed in 96-well plates and has the potential to be used as a high-throughput method. A clear induction of the expression of P-gp was demonstrated in the Caco-2 cells grown in the presence of vinblastine, as well as in the transfected cells, although to a lesser extent. Both radioligands were shown to bind to P-gp. Verapamil was the radioligand of choice for further investigations due to its lower nonspecific binding to the transporter preparation. Kinetics as well as specificity of the binding of verapamil to the P-gp preparation were demonstrated. A two-affinity model was found to adequately describe the data derived from saturation as well as from competition experiments, in accordance with previous findings on two exsorption sites for P-gp. The binding properties of [3H]verapamil and [3H]vinblastine to a P-gp preparation derived from induced Caco-2 cells are described. The concentration-dependent displacement of the radioligand by nonlabeled substrates for P-gp should be a suitable principle for the determination of drug affinity to the respective binding sites at the human intestinal multidrug transporter P-gp.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9862789

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.

Authors:  Yoko Honda; Fumihiko Ushigome; Noriko Koyabu; Satoshi Morimoto; Yukihiro Shoyama; Takeshi Uchiumi; Michihiko Kuwano; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

2.  Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors.

Authors:  Timo Korjamo; Jukka Mönkkönen; Jouko Uusitalo; Miia Turpeinen; Olavi Pelkonen; Paavo Honkakoski
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

3.  Interaction of common azole antifungals with P glycoprotein.

Authors:  Er-jia Wang; Karen Lew; Christopher N Casciano; Robert P Clement; William W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  The detergent-soluble maltose transporter is activated by maltose binding protein and verapamil.

Authors:  R Reich-Slotky; C Panagiotidis; M Reyes; H A Shuman
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.

Authors:  J Gao; O Murase; R L Schowen; J Aubé; R T Borchardt
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

7.  Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).

Authors:  U Schmitt; A Abou El-Ela; L J Guo; H Glavinas; P Krajcsi; J M Baron; C Tillmann; C Hiemke; P Langguth; S Härtter
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

8.  Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers.

Authors:  Hidetoshi Arima; Kiyokazu Yunomae; Tadatoshi Morikawa; Fumitoshi Hirayama; Kaneto Uekama
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

9.  P-Glycoprotein attenuates brain uptake of substrates after nasal instillation.

Authors:  Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

10.  Cost, effectiveness and environmental relevance of multidrug transporters in sea urchin embryos.

Authors:  Bryan J Cole; Amro Hamdoun; David Epel
Journal:  J Exp Biol       Date:  2013-08-02       Impact factor: 3.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.